Recommendation

  1. Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastasis: histology, multiplicity, surgery and survival. Cancer 1996;78:1781-8.
  2. Posner. Management of brain metastasis. Rev Neurol 1992;148:477-87.
  3. Posner JB. Intracranial metastases. Hoofdstuk 5 in: Neurologic complications of cancer. FA Davis Co, Philadelphia, 1995.
  4. Posner JB, Chernik NL. Intracranial metastasis from systemic cancer. Adv Neurol 1978;19:579-592.
  5. Greenberg HS, Chandler WF, Sandler HM. Brain tumors.Oxford University Press. New York, Oxford, 1999.
  6. Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with cancer. Ann Neurol 1992;31:268-73.
  7. Cherryman GR, Olliff JFC, Golfieri R et al. A prospective comparison of Gd-DTPA-enhanced MRI and contrast-enhanced CT-scanning in the detection of brain metastases arising from small cell lung cancer. Contrast Media in MRI, International workshop Berlin Feb 1-3, 1990 (Eds. Dinger JC et al.), Medicom, 1990.
  8. Coulam CM, Seshul M, Donaldson Jl. Intracranial ring lesions: Can we differentiate by compu­ted tomography? Invest Radiol 1980;15:103-112.
  9. Davis PC, Hudgins PA, Peterman SB et al. Diagnosis of cerebral metastases: Double-dose delayed CT vs contrast-enhanced MR imaging. Am J Neurorad 1991;12:293-300.
  10. Friedman WA, Sceats AJ Jr, Nestok BR. The incidence of unexpected findings in an image-guided biopsy series: A review of 100 consecutive cases. Neurosurgery 1989;25:180-184.
  11. Simpson RK, Sirbasku DM, Baskin DS, et al. Solitary brainstem metastasis: Comparisons of x-ray computed tomography and magnetic resonance imaging to pathology. J Neurooncol 1987;5:57-63.
  12. Sze G, Milano E, Johnson C, et al. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. Am J Neuroradiol 1990;11:785-791.
  13. Taphoorn MJ, Heimans JJ, Kaiser MC, et al. Imaging of brain metastases. Comparison of computerized tomography (CT) and magnetic resonance imaging (MRI). Neuroradiology 1989;31(5):391-395.
  14. Yuh WT, Engelken JD, Muhonen, et al. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. Am J Neuroradiol 1992;13:335-354.
  15. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastasis. J Neurooncol 1999;44:275-81.
  16. Patchell RA, Tibbs PA, Walsh JW, et al. A  randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:­494-500.
  17. Grszesiakowska U, Tacikowska M. An assessment of the effectiveness of magnetic resonance imaging with delayed sequences in the detection of metastatic lesions to the brain. Med. Sci. Monit 2002; 8(1): 21-24.
  18. Yuh WT, Tali ET, Nguyen HD, et.al. The effect of contrast dose,imaging time and lesion size in the detection of intracerebral metastasis. AJNR Am. J. Neuroradiol 1995; 16(2): 373-80.
  19. Knauth M, Forsting M, Hartmann M, et.al. MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer. AJNR Am. J. Neuroradiol. 1996; 17(10); 1853-9.
  20. Baleriaux D, Colosimo C, Ruscalleda J, et al. Magnetic resonance imaging of metastatic disease to the brain with gadobenetate dimeglumine. Neuroradiology 2002; 44(3): 191-203.
  21. Balla JI, Iansek R, Elstein A. Bayesian diagnosis in the presence of preexisting disease. Lancet 1985;I:326-9.
  22. Latief KH, White CS, Protopapas Z, et al. Search for a primary lung neoplasm in patients with brain metastasis.Am J Radiol 1997;168:1339-1344.
  23. Le Chevalier T, Smith FP, Caille P et al.: Sites of primary malignancies in patients presenting with cerebral metastases. Cancer 1985;56:880-882.
  24. Merchut MP. Brain metastasis from undiagnosed systemic neoplasms. Arch Intern Med 1989;149:1076-1080.
  25. van de Pol M, van Aalst VC, Wilmink JT et al: Brain metastases form an unknown primary tumour; which diagnostic procedures are indicated. J Neurol Neurosurg Psych 1996; 61: 321-323.
  26. Ruda R, Borgogne M, Benech F et al. Brain metastasis from unknown primary tumor. J Neurol 2001;248:394-8.
  27. Maesawa S, Kondziolka D, Thompson TD et al. Brain metastasis in patients with no known primary tumor. Cancer 2000;89:1095-1101.
  28. Nguyen LN, Maor MH, Oswald MJ. Brain metastasis as the only manifestation of an undetected primary tumor. Cancer 1998;83:2181-4.
  29. Lagerwaard FJ, Levendag PC, Nowak PJCM et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803.
  30. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980;7:529-541.
  31. Arbit E, Wronski M, Galicich JH. Surgical resection of brain metastases in 670 patients: the Memorial Sloan-Ketering Cancer experience, 1972-1992. J Neurosurg 1994;80:386.
  32. Noordijk EM, Vecht CT, Haaxma-Reiche H et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711-7.
  33. Jeremic B, Becker G, Palsswilm L et al. Activity of extracranial metastases as a prognostic factor influencing survival after radiosurgery of brain metastases. J Cancer Res Clin Oncol 2000;126(8):475-80.
  34. Gaspar LE, Scott C, Murray K et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-6.
  35. Foy et al: Do prophylactic anti-convulsant drugs alter the pattern of seizures after craniotomy? J Neurol Neurosurg Psych 1992; 55: 753-757.
  36. Glantz M. Double-blind randomized placebo-controlled trial of anticonvulsant prophy­laxis in adults with newly diagnosed brain metastases. Proc ASCO 1994;13:176.
  37. Vecht CJ, Hovestadt A, Verbiest HB et al. Dose-effect relationship of dexamethason on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994;44(4):675-680.
  38. Overweg. Anti-epileptica. Ned Tijdschr v Geneeskd 1998; 142: 289-293.
  39. Auperin A, Arriaga R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476-484.
  40. Borgelt et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 1980;6:1-19.
  41. Gregor A, Cull A, Stephens RJ et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multi-centre randomised trial. Eur J Cancer 1997;33(11):1752-1758.
  42. Murray K, Scott C, Greenberg HM, et al. A Randomised phase III study of accelerated hyper­fractionated versus standard in patients with unresected brain metastases: a report of the radiation therapy oncology group (RTOG) 9104. Int J Rad Onc Phys 1994;39:571-574.
  43. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastases should be based on extracranial tumor activity and age. Int J Rad Oncol Phys 1994;29:711-717.
  44. Alexander E 3rd, Moraiarty TM, Davis RB et al. Stereotaxic radiosurgery for the definite, non-invasive treatment of brain metastases. J Natl Cancer Inst 1995;87(1):34-40.       
  45. Auchter RM, Lamond JP, Alexander E, et al. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 1996;35(1):27-35.
  46. Kondziolka D, Patel A, Lundsford LD et al. Stereotactic radiosurgery plus whole brain radiati­on versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999;45(2):427-34.
  47. Patchell RA, Tibbs PA, Regine WF, et al. Treatment of single brain metastases to the brain: a randomized trial. JAMA 1998;280(17):1485-1489.
  48. Mucacevic A, Kreth FW, Horstmann GA, Schmid-Elsaesser R, Wowra B, Steiger HJ, Reulen HJ. Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurgery 1999;91(1):35-43.
  49. Amedola BE, Wolf AL, Coy SR, Amendola M, Bloch L. Brain metastases in renal cell carcinoma: management with gamma knife radiosurgery et al. Cancer 2000;6(2):88-92.
  50. Goyal LK, Suh JH, Reddy CA, Barnett GH.The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. IJROBP 2000;47(4):1007-1012.
  51. Kim DG, Chung HT, Gwak HS, Paek SH, Jung HW, Han DH. Gamma knife radiosurgery for brain metastases: prognostic factors for survival and local control.
  52. Sneed PK, Suh JH, Goetsch SJ et al. A multi-institutional review of radiosurgery alone vs. Radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002; 53(3):519-26.
  53. EORTC 22952/26001: No radiotherapy vs. whole brain radiotherapy for 1 to 3 brain metastases from solid tumor after surgical resection or radiosurgery. A randomized phase III trial.
  54. Andrews DW, Scott CB, Sperduto PW et al. WBRT with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665-1672.
  55. Lederman G, Wronski M and Fine M. Fractionated radiosurgery for brain metastases in 43 patients with breast carcinoma. Breast Cancer Res Treat 2001;65(2):145-54.
  56. Ikushima H, Tokuuye K, Sumi M et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 48(5):1389-93.
  57. Wong et al. Int J Radiat Oncol Biol Phys 1996; 34(3):585-90.
  58. Cooper JS, Steinfeld AD, Lerch JA. Cerebral metastases: value of re-irradiation in selected patients. Radiology 1990;17:883-5.
  59. Shehata MK, Young B, Reid B et al. Stereotactic radiosurgery of 468 brain metastases < or = 2 cm: implications for SRS dose and WBRT. Int J Radiat Oncol Biol Phys 2004;59(1): 87-93.
  60. Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single brain metastasis: radiot­herapy alone or combined with neurosurgery? Ann Neurol 1993;33:58-590-595.
  61. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess te efficacy of surgery in addition to radiotherapy in patients with a single brain metastasis. Cancer 1996;78:1470-1476.
  62. Fadul C et al. Cerebellar metastases: diagnostic and management considerations. J Clin Oncol1987;5:1107-1115.
  63. IwadateY et al. Significance of surgical resection for the treatment of multiple brain metastases. Anticancer Res 2000;20:573-7.
  64. Bokemeyer C, Nowak P, Haupt A, et al. Treatment of brain metastases in patients with testicu­lar cancer. J Clin Oncol 1997; 15:1449‑54.
  65. Boogerd W, Dalesio O, Bais EM et al. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69:97-980.
  66. Bower M, Newlands ES, Holden L, et al. EMA/CO for high‑risk gestational trophoblastic tumors: results from a cohort of 272 patients [published erratum appears in J Clin Oncol 1997 Sep;15(9):3168]. J Clin Oncol 1997; 15:2636‑­43.
  67. Carey RW, Davis JM, Zervas NT. Tamoxifen‑induced regression of cerebral metastases in breast carcinoma. Cancer Treat Rep 1981; 65:793‑5.
  68. Evans AC, Jr., Soper JT, Clarke Pearson DL, et al. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 1995; 59:226‑30.
  69. Gerl A, Clemm C, Schmeller N et al. Advances in the management of metastatic non-semino­matous germ cell tumours during the cisplatin era: a single institution experience. Br J Cancer 1996;74(8):1280-5.
  70. Kochhar R, Frytak S, Shaw EG. Survival of patients with extensive small‑­cell lung cancer who have only brain metastases at initial diagnosis. Am J Clin Oncol 1997; 20:125‑7.
  71. Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small‑cell lung cancer: a review. J Clin Oncol 1992; 10:1498‑502.
  72. Logothetis CJ, Samuels ML, Trindade A. The management of brain metastases in germ cell tumors. Cancer 1982;49(1):12-18
  73. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58:832‑9.
  74. Bindal RK, Sawaya R, Leavens ME, et al.. Reoperation for recurrent metastatic brain tumor. J Neurosurg 1995;83:600-4.
  75. Bindal RK, Sawaya R, et al. Surgical treatment of multiple brain metastases. J Neurosurg 1993;79:210-6.
  76. Kaba SE, Kyritsis AP, Hess K et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumor. J Clin Oncol 1997;15:1063-70.
  77. Arbit E, Wronski M, Burt M, Gallich JH. The treatment of patients with recurrent brain metastases. Cancer 1995;76:765-73.

 



 

Authorization date and validity

Last review : 01-07-2011

Last authorization : 01-07-2011

The period of validity of the guideline (maximum of 5 years) is being monitored by IKNL. For various reasons, it may be necessary to revise the guideline earlier than intended. Sections of the guideline will be amended in the interim, when required.

Initiative and authorization

Initiative : Nederlandse Vereniging voor Neurologie

Authorized by:
  • Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose
  • Nederlandse Vereniging voor Medische Oncologie
  • Nederlandse Vereniging voor Neurochirurgie
  • Nederlandse Vereniging voor Neurologie
  • Nederlandse Vereniging voor Radiotherapie en Oncologie
  • Verpleegkundigen en Verzorgenden Nederland
  • Nederlandse Vereniging voor Psychosociale Oncologie
  • Nederlands Instituut van Psychologen

Scope and target group

Objective

The guideline covers the processes of diagnosis, treatment, information provision and guidance of adult patients with metastases in the brain originating from solid tumours, thereby focusing on topical clinical problems encountered in daily practice. The guideline's recommendations aim to aid practitioners in their decision-making support when facing these problems. The recommendations are based on the highest available grade of scientific evidence and on consensus within the guideline development group. The guideline provides information on how the recommendations have been reached from the evidence.

 

The guideline may be used to provide information to patients and offers points of reference for transmural agreements or local protocols to facilitate implementation.

Users

The guideline is intended for all professionals involved in the diagnostics, treatment and guidance of adult patients with brain metastases of solid tumours. These professionals include:

  • Primary specialists: neurologists, neurosurgeons, radiotherapists, medical oncologists, pulmonologists, (oncology) nurses, general practitioners, specialists (working) in palliative care
  • Supporting specialists: radiologists, pathologists
  • Healthcare providers specialised in psychosocial care: social workers, psychologists, psychiatrists and geriatric medicine specialists

 

Members of the guideline panel

2011:

Chair:

mw. dr. J.M.M. Gijtenbeek, neuroloog, Universitair Medisch Centrum St Radboud, Nijmegen

Other members:

dr. L.V. Beerepoot, medisch oncoloog, St. Elisabeth Ziekenhuis, Tilburg

dr. W. Boogerd, neuroloog, Nederlands Kanker Instituut / Antoni van Leeuwenhoekziekenhuis, Slotervaartziekenhuis, Amsterdam

mw. S. Bossmann, nurse practitioner, Universitair Medisch Centrum St Radboud Nijmegen

mw. dr. M. van Dijk, internist-oncoloog, Maastricht Universitair Medisch Centrum, Maastricht

mw. dr. A.C. Dingemans, longarts, Maastricht Universitair Medisch Centrum, Maastricht

mw. dr. C. van Es, radiotherapeut-oncoloog, Utrecht Universitair Medisch Centrum, Utrecht, niet actief betrokken (is betrokken geweest bij het initiëren van de werkgroep maar kon vanwege onvoorziene omstandigheden niet aan de totstandkoming van de richtlijn meewerken)

dr. A. de Graeff, medisch oncoloog, Utrecht Universitair Medisch Centrum, Utrecht

dr. P.E.J. Hanssens, radiotherapeut-oncoloog, Gamma Knife Centrum, Tilburg

dr. H.F.M. van der Heijden, longarts, Universitair Medisch Centrum St Radboud, Nijmegen

dr. M.A.A.M. Heesters, radiotherapeut-oncoloog Universitair Medisch Centrum Groningen, Groningen

dr. P.A. M. Hofman, neuroradioloog, Maastricht Universitair Medisch Centrum, Maastricht

dr. R.L.H. Jansen, medisch oncoloog, Maastricht Universitair Medisch Centrum, Maastricht, niet actief betrokken

drs. E. Kurt, neurochirurg, Medisch Centrum Alkmaar

dr. F. J. Lagerwaard, radiotherapeut-oncoloog, Vrije Universiteit Medisch Centrum, Amsterdam

mw. prof.dr. J.B. Prins, klinisch psycholoog, Universitair Medisch Centrum St Radboud, Nijmegen

drs. J.H.C. Voormolen, neurochirurg, Leids Universitair Medisch Centrum, Leiden

drs. V.K.Y. Ho, epidemioloog/procesbegeleider, Integraal Kankercentrum Nederland (IKNL), locatie Utrecht

mw. M.L. van de Kar, ambtelijk secretaris, Landelijke Werkgroep Neuro-Oncologie (LWNO), Bussum

Ondersteuning methodologie

mw. dr. M. Brink, epidemioloog, IKNL, locatie Utrecht

drs. J.M. van der Zwan, MSc, epidemiologisch onderzoeker, IKNL, locatie Enschede

 

Leden werkgroep voorgaande revisie (2004)

dr. R.H. Boerman, neuroloog, Rijnstate Ziekenhuis, Arnhem (voorzitter)

dr. W. Boogerd, neuroloog, Nederlands Kanker Instituut / Antoni van Leeuwenhoekziekenhuis, Slotervaartziekenhuis, Amsterdam

mw. dr. W.M.H. Eijkenboom, radiotherapeut-oncoloog, Daniel den Hoed Kliniek, Rotterdam

dr. P.E.J. Hanssens, radiotherapeut-oncoloog, Dr. Bernard Verbeeten Instituut, Tilburg

dr. R.L.H. Jansen, medisch oncoloog, Academisch Ziekenhuis Maastricht

dr. F. J. Lagerwaard, radiotherapeut-oncoloog, Vrije Universiteit Medisch Centrum, Amsterdam

prof.dr. C.J.A. Punt, inetrnist-oncoloog, Academisch Ziekenhuis Nijmegen

drs. J.H.C. Voormolen, neurochirurg, Leids Universitair Medisch Centrum, Leiden

prof.dr. J.T. Wilmink, neuroradioloog, Academisch Ziekenhuis Maastricht

dr. J.G. Wolbers, neurochirurg, Academisch Ziekenhuis Dijkzigt, Rotterdam

 

 

Declaration of interest

All guideline working group members were asked to fill in a conflict of interest declaration, in which they stated ties with the medical industry at the start and completing the guideline process. An overview of these conflict of interest declarations can be found below. The remaining guideline working group members have declared that at this moment or in the last three years they have not performed any activities on invitation or with subsidy/sponsoring by the medical industry.
   

Lid

Firma

Activiteit

Overig

Dr. L.V. Beerepoot

Pfizer

Merck

Cephalon

consultatie / advisering

congres

congres

congres

Dr. W. Boogerd

Mundipharma

 

congres

Dr. M. van Dijk

Schering Plough

 

congres

Dr. A.C. Dingemans

Roche

 

Lilly

Astra Zeneca

 

Glaxo

consultatie / advisering / wetenschappelijk onderzoek

consultatie / advisering

consultatie / advisering / wetenschappelijk onderzoek

consultatie / advisering / wetenschappelijk onderzoek

congres

 

cursus

Dr. C.A. van Es

Elektra

 

congres

Dr. A. de Graeff

 

Nycomed

Wyeth

consultatie / advisering

consultatie / advisering

 

Dr. P.A.M. Hofman

Strijker NL B.V.

Medtronics Spinal

Bayer Health Care

Johnson & Johnson

 

congres

congres

congres

congres

Dr. H.F.M. van der Heijden

Astra Zeneca

Sanofi Aventis

Lilly

 

Roche

consultatie / advisering

consultatie / advisering

consultatie / advisering / wetenschappelijk onderzoek

 

congres

congres

congres

 

congres

Dr. R.L.H. Jansen

Pfizer

Roche

Sanofi Aventis

Diverse firma's

 

 

wetenschappelijk onderzoek

studies

congres

congres

congres

Dr. F.J. Lagerwaard

Roche Nederland

Roche NL-longadviesraad

Brain Lab

Varian Medical Systems

wetenschappelijk onderzoek

consultatie / advisering

 

 

 

congres

congres

   

Method of development

Evidence based

Implementation

Considerations concerning the implementation of the guideline as well as the feasibility of recommendations have been taken into account as much as possible in drafting the revised guideline.

 

The guideline is summarised and may be consulted in its entirety on http://www.oncoline.nl/. The guideline has been brought to the attention of members of the LWNO, hospitals in the Netherlands, oncology commissions, as well as the scientific and professional associations involved. To further stimulate awareness and implementation of the guideline, regional tumour working groups on neuro-oncology of IKNL were invited to discuss its recommendations.

 

Given the highly progressive and unfavourable course of the disease, the guideline development group decided not to develop care indicators to measure the level of guideline implementation.